Vilanterol is an ultra-long-acting β₂-adrenergic receptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Vilanterol works by stimulating beta-2 receptors in the lungs, helping relax and open the airways, making breathing easier for patients with obstructive lung diseases. It is often combined with inhaled corticosteroids or other bronchodilators for long-term management of COPD and asthma, though it is not intended for relief of acute symptoms.
Parent: Vilanterol
Parent: Vilanterol
Parent: Vilanterol
Parent: Vilanterol/ Vilanterol Trifenatate
Parent: Vilanterol
Parent: Vilanterol
Parent: Vilanterol
During the production and storage of Vilanterol, impurities may form, and these must be controlled to ensure the drug’s safety and efficacy. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), set guidelines for permissible impurity levels in Vilanterol formulations.
Vilanterol is a long-acting beta-2 agonist (LABA), a type of bronchodilator used to help open the airways in the lungs. It is commonly prescribed in combination with other medications to manage respiratory conditions like COPD and asthma.
Vilanterol is a LABA (long-acting beta-2 agonist), designed for prolonged bronchodilation and is typically used once daily. Unlike SABAs (short-acting beta-2 agonists), which are used for quick relief, LABAs like Vilanterol are used for long-term control and are not for immediate symptom relief.
Vilanterol itself does not contain steroids, but it is often combined with an inhaled corticosteroid (such as fluticasone) in combination inhalers. The corticosteroid component works to reduce inflammation, while Vilanterol acts as a bronchodilator.
No, Vilanterol and Salmeterol are different, although both are LABAs. Vilanterol has a more rapid onset of action and a longer duration compared to Salmeterol. The choice between the two often depends on the specific needs of the patient and the prescribing physician’s guidance.
